FTO and cancer: Noticeably, inhibitors of FTO and ALKBH5 are effective in certain subtypes of AMLs and some solid tumors where FTO or ALKBH5 is overexpressed and promotes tumorigenesis, suggesting that these inhibitors may have promising and broad roles in cancer therapy.